Adempas is approved to treat adults with:
- Chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or that cannot be treated with surgery (inoperable)
- Pulmonary arterial hypertension (PAH) (WHO Group 1)
The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.



Reviews
There are no reviews yet.